Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

Pasithea Therapeutics will make its first public disclosure of initial Part A Phase 1/1b clinical data for PAS-004 in adults with NF1-associated neurofibromas at the European Neurofibromatosis Conference in Vienna on November 12–14, 2026. The company was selected for an oral presentation covering cutaneous neurofibromas and a poster presentation covering plexiform neurofibromas. No efficacy, safety, PK, or other clinical-result data were disclosed, limiting the immediate valuation impact ahead of the conference.

Analysis

KTTA’s near-term setup is principally an event-timing trade, not a fundamental de-risking. Conference selection validates enough dataset maturity to support disclosure, but provides no independent read-through on response rate, durability, tolerability, dose selection, or the cash runway needed to reach a registrational path. In a thinly traded micro-cap, the announcement can create a short-lived pre-conference bid; absent intervening data, that premium is likely vulnerable to financing concerns and profit-taking well before November.

The key competitive hurdle is not simply showing activity: approved NF1 MEK therapy sets a high bar on chronic tolerability, particularly for a population requiring prolonged treatment. PAS-004 needs to demonstrate a meaningful differentiation in exposure consistency, dermatologic/GI toxicity, cardiac/ocular monitoring burden, or durability versus selumetinib’s established profile; modest tumor shrinkage alone is unlikely to support a durable valuation rerating. A positive adult dataset could nonetheless expand strategic relevance to larger RAS/MAPK franchise holders, while ambiguous safety data would impair both NF1 and broader oncology optionality.

Consensus may overvalue the oral-presentation format as a quality signal. Scientific-program selection is not equivalent to peer-validated efficacy, and early Part A cohorts may be too small or heterogeneous for cross-trial comparisons. The investable catalyst is the actual November dataset and its accompanying update on dose expansion, enrollment pace, and cash use; until then, this is a watchlist name rather than a core biotech long.

Key Decisions for Investors

• Do not initiate a fundamental long in KTTA solely on this release; reassess after the November data disclose evaluable-patient count, confirmed response criteria, duration of response, discontinuations, and dose-limiting toxicities.
• For event-driven accounts, consider only a small tactical long into the November presentation if liquidity is adequate and the stock remains below the post-announcement high; size for a binary 30-50% downside on ambiguous safety/efficacy, with profits taken ahead of detailed-results release rather than held on presentation-format optics.
• Set a diligence alert for the next quarterly filing: cash balance, quarterly operating burn, ATM/shelf capacity, and any going-concern language are more likely than this conference notice to determine the next 1-3 month equity move.
• Falsify a constructive post-data thesis if PAS-004 shows clinically material class toxicities, weak durability despite initial shrinkage, or management cannot identify a dose suitable for chronic administration; these outcomes would undermine differentiation versus existing MEK-inhibitor standards.